Alliancebernstein L.P. Has $229.10 Million Position in Danaher Corporation $DHR

Key Points

• Alliancebernstein L.P. reduced its stake in Danaher Corporation by 7.2%, now holding approximately $229.1 million worth of shares.
• Institutional investors own 79.05% of Danaher's stock, with significant increases in holdings reported by Vanguard, Price T Rowe Associates, and Invesco.
• Danaher reported $1.80 earnings per share for the last quarter, exceeding estimates, and projects FY 2025 EPS guidance in the range of 7.700-7.800.

Alliancebernstein L.P. reduced its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 7.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,117,574 shares of the conglomerate's stock after selling 86,902 shares during the quarter. Alliancebernstein L.P. owned 0.16% of Danaher worth $229,103,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC increased its stake in shares of Danaher by 98.3% during the 1st quarter. AQR Capital Management LLC now owns 747,389 shares of the conglomerate's stock worth $150,427,000 after purchasing an additional 370,483 shares during the last quarter. Advisors Asset Management Inc. grew its holdings in Danaher by 1.1% during the first quarter. Advisors Asset Management Inc. now owns 6,493 shares of the conglomerate's stock worth $1,331,000 after purchasing an additional 73 shares during the period. Alyeska Investment Group L.P. increased its position in Danaher by 34.7% during the first quarter. Alyeska Investment Group L.P. now owns 1,066,380 shares of the conglomerate's stock worth $218,608,000 after buying an additional 274,765 shares during the last quarter. Amundi raised its stake in Danaher by 1.2% in the first quarter. Amundi now owns 3,053,611 shares of the conglomerate's stock valued at $605,153,000 after buying an additional 35,457 shares during the period. Finally, Aprio Wealth Management LLC raised its stake in Danaher by 35.5% in the first quarter. Aprio Wealth Management LLC now owns 1,887 shares of the conglomerate's stock valued at $387,000 after buying an additional 494 shares during the period. Institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on DHR shares. Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday, September 2nd. Guggenheim reaffirmed a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Wells Fargo & Company decreased their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Finally, Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Danaher Stock Performance

Shares of DHR stock traded down $3.97 on Tuesday, hitting $194.66. The company's stock had a trading volume of 1,003,413 shares, compared to its average volume of 4,123,806. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock's 50 day moving average is $201.95 and its 200-day moving average is $199.23. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The company has a market capitalization of $139.39 billion, a PE ratio of 41.42, a PEG ratio of 2.79 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 11.20% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.